Strategic Strigini and the European endeavor
This article was originally published in Scrip
Executive Summary
Bruno Strigini has just jetted back to London from Paris. There, he was visiting the largest cancer campus in Europe, Institut Gustave Roussy, to see "collaboration in practice" – something the French native is passionate about. The majority of his working life is spent at MSD country offices and with colleagues and policy leaders throughout Europe, in his role as president of MSD in Europe and Canada.
You may also be interested in...
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.